Tag: anti-PD1 therapy

Latest articles

focus on science and not geography

Greater global collaboration: Time to focus on science and not geography

The Pistoia Alliance is urging industry stakeholders worldwide to focus on science and not geography, in a call for greater global collaboration. More than 250...
Accelerating the MedTech landscape

Accelerating the MedTech landscape

The Academic Health Science Networks (AHSN) in partnership with the Association of British HealthTech Industries (ABHI) has launched a report on accelerating the MedTech...
Tescaro present data from the GARNET study on dostarlimab in endometrial cancer. 

Tescaro present data on dostarlimab in endometrial cancer

Tescaro release positive results from the GARNET study on dostarlimab in endometrial cancer.  TESARO, an oncology-focused business acquired by GlaxoSmithKline plc, presents data from the...

Popular articles

Bristol-Myers Squibb-Pfizer Alliance announces results from Phase 4 AUGUSTUS trial.

AUGUSTUS trial demonstrates favourable safety results

The Bristol-Myers Squibb-Pfizer Alliance has announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis ® (apixaban) versus vitamin K antagonists (VKAs) in patients...
Smart phone image: Digital partnerships in pharma

Digital partnerships in pharma and the NHS

Can pharma and the NHS equal the fast pace of change necessary to fully embrace technological innovation? Over the last few years, slowly but surely,...
Trial results of Brilinta for heart attack patients following thrombolysis shows it met safety endpoint in secondary analysis of Phase III TREAT trial

Analysis of trial results of Brilinta for heart attack patients following thrombolysis

Analysis of trial results of Brilinta for heart attack patients following thrombolysis shows it met safety endpoint in secondary analysis of Phase III TREAT trial. The secondary...
The future of genomics

The future of genomics and precision medicine

How is the use of genomics data enhancing our medical understanding and what does this mean for the future of precision medicine? Genomics is one of...
Farxiga reduced the relative risk of MACE by 16% in certain patients

Trial sub-analyses support CV effects of Farxiga in T2D

Positive results from a pre-specified sub-analysis of the Phase III DECLARE-TIMI 58 trial showed that Farxiga (dapagliflozin) reduced the relative risk of major adverse...